Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance
Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.
How this was made
The 30-second read
Why it matters
The earnings miss triggered a 3% pre‑market drop, highlighting investor sensitivity to guidance shortfalls in small‑cap biotech.
Market read
The report provides fresh earnings data that directly affected Aurinia's share price and may influence peer biotech valuations.
What to watch
Cash of $486.9 M provides runway; the PRESERVE study may unlock additional revenue streams.
Background
Aurinia Pharmaceuticals released its Q3 2026 earnings, reporting a miss on EPS and softening revenue guidance.
Ticker impact
Q3 earnings miss and guidance below consensus caused a 3.43% pre‑market decline in Aurinia stock.
likely further downside as investors price in weaker guidance and missed EPS.
The earnings miss and soft guidance are fresh primary data that directly moved the stock.
Market effects
May weigh on other biotech and pharma stocks, especially those with lupus or rare disease pipelines.
US biotech sector could see modest pullback in early trading.
Limited to investors tracking US biotech earnings; no broad macro impact.
Counterpoint
Strong cash balance and upcoming Phase 4 trial could support a rebound if data are positive.
Key entities
- companyAurinia Pharmaceuticals Inc.
US‑listed biopharmaceutical company focused on lupus nephritis therapy.
